Metastatic Breast Cancer in the Liver

Oncology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Delcath
DelcathQUEENSBURY, NY
1 program
1
Melphalan/HDS followed by Physician's choice of SOCPhase 21 trial
Active Trials
NCT06875128Recruiting90Est. Aug 2029

Trial Timeline

Clinical trial activity over time

2026
2027
2028
2029
DelcathMelphalan/HDS followed by Physician's choice of SOC

Clinical Trials (1)

Total enrollment: 90 patients across 1 trials

NCT06875128DelcathMelphalan/HDS followed by Physician's choice of SOC

Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease

Start: Jan 2026Est. completion: Aug 202990 patients
Phase 2Recruiting

Related Jobs in Oncology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 90 patients
1 companies competing in this space